Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company, has announced its plans to release its Q1 2023 financial results after the financial markets close on Wednesday, May 3, 2023. The announcement was made in a statement released via the Business Wire on April 11, 2023.
According to the statement, the company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its first-quarter 2023 financial and operating results. A live webcast of the call will be available on Tandem Diabetes Care’s Investor Center website, located at http://investor.tandemdiabetes.com in the “Events & Presentations” section.
Also Read:
Investors and analysts looking to participate in the conference call may access the call by phone by clicking on this link (https://register.vevent.com/register/BI21343b3e346b4b66923ccc4e1bd048e5), which will provide them with dial-in details, including a personal pin. An archive of the webcast will be available for 30 days following the event on Tandem Diabetes Care’s Investor Center website in the “Events & Presentations” section.
Tandem Diabetes Care is a global insulin delivery and diabetes technology company based in San Diego, California. The company creates new possibilities for people living with diabetes, their loved ones, and healthcare providers through a positively different experience. Its human-centered approach to design, development, and support delivers innovative products and services for people who use insulin.
Also Read:
Tandem manufactures and sells the t:slim X2 insulin pump with Control-IQ technology. The company’s product range also includes a range of diabetes management software products, such as the Tandem Device Updater, which allows patients to update their insulin pump from the comfort of their own homes.
Tandem Diabetes Care and Control-IQ are trademarks registered in the U.S. and/or other countries, and t:slim X2 is a trademark of Tandem Diabetes Care, Inc.
Also Read:
Investors and analysts are eagerly awaiting the announcement of Tandem Diabetes Care’s Q1 2023 financial results. The company has been growing rapidly in recent years and has proven itself to be a key player in the diabetes management technology sector. Its innovative products and services have been praised by patients and healthcare providers alike, and the company’s continued success is expected to drive significant interest in the financial markets.
Tandem Diabetes Care’s commitment to creating a positively different experience for patients and healthcare providers has set it apart from its competitors, and the company’s approach has been identified as a key driver of its success. Its continued focus on innovation and patient-focused design is expected to drive its growth in the coming years.
Also Read:
Investors and analysts looking for more information on Tandem Diabetes Care’s Q1 2023 financial results can tune in to the conference call and webcast on May 3, 2023. The live webcast will be available on Tandem Diabetes Care’s Investor Center website, located at http://investor.tandemdiabetes.com in the “Events & Presentations” section.
In Other News Around the World: